Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome

ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo Data Presented During Emerging Therapies Plenary Session at 2018 American Academy of Neurology Annual Meeting EMERYVILLE, Calif., April 27, 2018 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ:ZGNX),